Constellium to Report Fourth Quarter and Full Year 2024 Results on February 20, 2025
By:
Constellium Paris via
GlobeNewswire
February 05, 2025 at 08:00 AM EST
PARIS, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Constellium SE (NYSE: CSTM) will host a conference call and webcast on Thursday, February 20, 2025, at 10:00 AM (Eastern Time) to announce its fourth quarter and full year 2024 results. The press release will be sent before market opening. The conference call will be hosted by Jean-Marc Germain, Chief Executive Officer, and Jack Guo, Senior Vice President and Chief Financial Officer. Details of the conference call, webcast and accompanying presentation will be available on the Constellium Investor Relations page at: https://www.constellium.com/investors/financial-results The webcast can be accessed live at https://events.q4inc.com/attendee/199667050 To participate by telephone, please use this link or dial the following number and enter access code 175417 to be connected to the Constellium earnings call: United States: +1 646 787 9445 An archived recording of the conference call will also be available at www.constellium.com for three weeks. About Constellium Constellium (NYSE: CSTM) is a global sector leader that develops innovative, value-added aluminum products for a broad scope of markets and applications, including aerospace, packaging and automotive. Constellium generated $7.8 billion of revenue in 2023.
More NewsView MoreVia MarketBeat
Tickers
MSFT
MarketBeat Week in Review – 12/1 - 12/5 ↗
Today 7:00 EST
Rocket Lab’s Big Rebound? Analysts Suggest the Dip's a Gift ↗
December 05, 2025
Via MarketBeat
Tickers
RKLB
Meta’s AI Moment? New SAM 3 Model Has Wall Street Turning Bullish ↗
December 05, 2025
Snowflake Stock: The Dip That Smart Investors Are Buying Right Now ↗
December 05, 2025
Via MarketBeat
Recent QuotesView More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
|

